SecBot SecBot
8-K ·Filed Nov 5, 2026

IOVA

IOVANCE BIOTHERAPEUTICS, INC.
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 10h ago SEC0001193125-26-450084
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor upcoming sBLA submission for lifileucel in 2L mNSCLC in 2027 and the OPTILISM Phase 3 trial initiation, as NSCLC represents a 10x larger opportunity than the current melanoma market. The raised guidance and strong Q3 revenue growth (~80% YoY) suggest accelerating commercial adoption of Amtagvi.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

IOVA drug pipeline →

Amtagvi

● Neutral Named in this 8-K
Impact
Phase
Approved (accelerated approval)
Time to market
Already approved and marketed (FDA accelerated approval Feb 16, 2024). Confirmatory Phase 3 (TILVANCE-301) is ongoing to convert to full approval.
Next catalyst
BLA filing · 2027

What to watchWatch for TILVANCE-301 Phase 3 interim or topline results (undated but the key catalyst for converting accelerated to full approval and expanding into frontline) and quarterly revenue growth trajectory, Q2 2026 guidance is $86M-$88M. Also monitor IOV-LUN-202 NSCLC registrational data (Fast Track, potential launch 2H27). At ~$3.97 with a mean analyst target of $8.80 (177% upside), the stock prices in meaningful commercial execution but not a TILVANCE-301 success.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$8.04
T+0 close · Nov 5, 2026 · via day close
Latest settled
−3.48%
T+5 · $7.76 · next T+20 in 20d
Vs SPY
−6.08%
α at T+5
Latest observation
−2.99%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $8.04entry
  2. T+1 · 8d ago +1.62%α −0.75% · $8.17
  3. T+5 · 4d ago −3.48%α −6.08% · $7.76
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Iovance Biotherapeutics filed an 8-K to update its corporate presentation, which includes a raised full-year 2026 revenue guidance from $350M-$370M to $410M-$420M (midpoint increase of ~15%), reported Q3 2026 revenue of ~$122M (~80% YoY growth), and disclosed interim clinical data across its TIL pipeline including NSCLC and sarcoma programs. The filing is a routine business update with no material new corporate events.

Key Facts

  • Full year 2026 revenue guidance raised from $350M-$370M to $410M-$420M, a ~15% midpoint increase of $55M
  • Q3 2026 revenue of ~$122M, representing ~80% year-over-year growth and ~22% sequential growth
  • Q3 2026 margin from cost of sales (excl. D&A) of ~60%, 54% year-to-date
  • Cash, cash equivalents, short-term investments and restricted cash of ~$382M as of September 30, 2026, with runway well into 2029
  • Interim data from IOV-LUN-202 in non-squamous NSCLC showed 24.6% ORR (17/69) and 59.1% ORR (13/22) in a biomarker-enriched population
  • Interim data from SARATOGA in soft tissue sarcomas showed 55.6% ORR (5/9) in DDLPS and UPS
  • First 5 evaluable patients in ENDURANCE endometrial cancer trial showed 40% ORR and 100% DCR
  • Planned sBLA submission for lifileucel in 2L mNSCLC in 2027; OPTILISM Phase 3 trial in frontline NSCLC to start in 2027
  • Over 100 authorized treatment centers in U.S., Canada and Australia; over 1,000 commercial patients treated

Financial Impact

FY26 revenue guidance raised by ~$55M at midpoint to $410M-$420M; Q3 revenue ~$122M; cash ~$382M

revenuecash positioncost of sales margin

Risk Factors

  • Clinical trial results are interim and may not be confirmed in final analyses or support regulatory approvals
  • Forward-looking statements and guidance are subject to risks including manufacturing, payor coverage, and competitive dynamics
  • The company is not yet profitable and may not generate sufficient revenue to achieve profitability

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-450084
Document: iova-20261105.htm0001193125-26-450084
Document: 0001193125-26-450084-index-headers.html0001193125-26-450084
Document: 0001193125-26-450084-index.html0001193125-26-450084
Document: 0001193125-26-450084.txt0001193125-26-450084

Track record

21 reports on IOVA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $8.04 Now $7.55 −6.09% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
  6. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
  8. Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
  9. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
  10. Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 5h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026